Literature DB >> 25528311

Comparison of a morning polypill, evening polypill and individual pills on LDL-cholesterol, ambulatory blood pressure and adherence in high-risk patients; a randomized crossover trial.

M Lafeber1, D E Grobbee2, I M Schrover3, S Thom4, R Webster5, A Rodgers5, F L J Visseren3, M L Bots2, W Spiering6.   

Abstract

AIMS: Cardiovascular polypills are a novel strategy in the prevention of cardiovascular disease. Based on considerations about the effectiveness, the individual pills of a polypill are taken at different times of the day. This study aimed therefore to compare the use of a polypill in the morning, in the evening or the individual components taken at their usual times on cardiovascular risk factors and patient acceptability.
METHODS: The study was a randomized three-period crossover trial. Seventy-eight patients with established cardiovascular disease were randomly allocated to the use of polypill (aspirin 75 mg, simvastatin 40 mg, lisinopril 10mg and hydrochlorothiazide 12.5mg) in the morning, in the evening or use of the individual agents taken at different time points (Trial: NCT01506505).
RESULTS: Using the polypill in the evening resulted in a 0.2 mmol/L (95%-confidence interval (CI): 0.1 to 0.3) lower fasting LDL-cholesterol compared to the use in the morning, and not statistically significantly different mean 24-hour systolic BP (mean difference: 0.7 mmHg; 95%-CI; -2.1 to 3.4). Compared to the use of the individual agents, the mean LDL-cholesterol was 0.2 mmol/L (95%-CI: 0.1 to 0.3) higher when using the polypill in the morning, but not statistically significantly different when used in the evening (mean difference: -0.1 mmol/L; 95%-CI: -0.1 to 0.0). Furthermore, there were no differences in mean 24-hour systolic BP with morning use (mean difference: 0.4 mmHg; 95%-CI; -1.5 to 2.3) or evening use (mean difference: 1.0mmHg; 95%-CI; -0.8 to 2.8) of the polypill compared to the individual agents. The adherence was 5.2% (95%-CI: 1.4 to 9.1) higher with morning use of the polypill and 5.0% (95%-CI: 1.5 to 8.5) higher with evening use compared to the individual agents. Treatment with the polypill was preferred by 92% of the participants.
CONCLUSION: The use of a polypill in the evening was more effective in lowering LDL-cholesterol, and resulted in not statistically significantly different ambulatory BP levels compared to the use of a polypill in the morning. Therapy with a polypill was associated with an increased adherence. The polypill is highly preferred by patients, demonstrating a potential role for the polypill in the prevention of cardiovascular disease.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Aspirin; Bloodpressure lowering agent; Cardiovascular prevention; Fixed-dose combination pill; Polypill; Statin

Mesh:

Substances:

Year:  2014        PMID: 25528311     DOI: 10.1016/j.ijcard.2014.11.176

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  13 in total

Review 1.  Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.

Authors:  Ehete Bahiru; Angharad N de Cates; Matthew Rb Farr; Morag C Jarvis; Mohan Palla; Karen Rees; Shah Ebrahim; Mark D Huffman
Journal:  Cochrane Database Syst Rev       Date:  2017-03-06

Review 2.  [Management of different cardiovascular risk factors with a combination tablet (polypill)].

Authors:  P Bramlage; W März; D Westermann; B Weisser; J H Wirtz; U Zeymer; P Baumgart; G van Mark; U Laufs; B K Krämer; T Unger
Journal:  Herz       Date:  2017-03-24       Impact factor: 1.443

Review 3.  Chronotherapy for Hypertension.

Authors:  N P Bowles; S S Thosar; M X Herzig; S A Shea
Journal:  Curr Hypertens Rep       Date:  2018-09-28       Impact factor: 5.369

Review 4.  Multifactorial Prevention of Cardiovascular Disease in Patients with Hypertension: the Cardiovascular Polypill.

Authors:  M Lafeber; W Spiering; F L J Visseren; D E Grobbee
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

Review 5.  Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.

Authors:  Ambuj Roy; Nitish Naik; K Srinath Reddy
Journal:  Curr Cardiol Rep       Date:  2017-05       Impact factor: 2.931

6.  Effects of green tea extract on overweight and obese women with high levels of low density-lipoprotein-cholesterol (LDL-C): a randomised, double-blind, and cross-over placebo-controlled clinical trial.

Authors:  Lin-Huang Huang; Chia-Yu Liu; Li-Yu Wang; Chien-Jung Huang; Chung-Hua Hsu
Journal:  BMC Complement Altern Med       Date:  2018-11-06       Impact factor: 3.659

7.  Treatment patterns and adherence to antihypertensive combination therapies in Japan using a claims database.

Authors:  Takayuki Ishida; Akinori Oh; Shinzo Hiroi; Yukio Shimasaki; Nobuhiro Nishigaki; Takuya Tsuchihashi
Journal:  Hypertens Res       Date:  2018-11-16       Impact factor: 3.872

Review 8.  Prevention of Hypertensive Disorders of Pregnancy: a Novel Application of the Polypill Concept.

Authors:  J L Browne; K Klipstein-Grobusch; A Franx; D E Grobbee
Journal:  Curr Cardiol Rep       Date:  2016-06       Impact factor: 2.931

9.  Stroke Minimization through Additive Anti-atherosclerotic Agents in Routine Treatment (SMAART): study protocol for a randomized controlled trial.

Authors:  Fred Stephen Sarfo; Osei Sarfo-Kantanka; Sheila Adamu; Vida Obese; Jennifer Voeks; Raelle Tagge; Vipin Sethi; Bruce Ovbiagele
Journal:  Trials       Date:  2018-03-14       Impact factor: 2.279

10.  Meta-Analysis of Studies Comparing Single and Multi-Tablet Fixed Dose Combination HIV Treatment Regimens.

Authors:  P G Clay; S Nag; C M Graham; S Narayanan
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.